Pulmonary Hypertension
The clinical research activity at Thoraxklinik Heidelberg gGmbH is centered on pulmonary hypertension, with a strong focus on conditions that affect the pulmonary circulation and heart-lung interaction. The main disease areas include pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, reflecting interest in both vascular remodeling and persistent obstruction of the pulmonary vessels.
- Pulmonary arterial hypertension
- Chronic thromboembolic pulmonary hypertension
- Pulmonary vascular disease
Research activity also extends to early-stage pulmonary vascular disease, with attention to identifying cardiovascular changes linked to evolving pressure overload in the right heart.
Right Heart Structure and Function
Another key area of interest is the assessment of right ventricular and right atrial remodeling in patients with pulmonary vascular disorders. The trials place emphasis on cardiac chamber size and functional adaptation as markers of disease burden in pulmonary hypertension.
- Right ventricular size
- Right atrial area
- Cardiac remodeling
Echocardiography is used to track structural changes in the right heart, supporting interest in how pulmonary vascular disease affects cardiac performance over time.
Pulmonary Vascular Resistance
The sponsor also focuses on hemodynamic features of pulmonary vascular disease, particularly pulmonary vascular resistance as a marker of disease severity and treatment response. This area is relevant to both established pulmonary arterial hypertension and earlier disease states that may progress toward clinically significant vascular obstruction.
- Pulmonary vascular resistance
- Hemodynamic burden
- Early pulmonary vascular disease
Interest in vascular load reflects the clinic’s emphasis on measurable cardiopulmonary endpoints in patients with progressive pulmonary vascular disease.
Riociguat in Pulmonary Vascular Disorders
The funded studies include research on riociguat in pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and incipient pulmonary vascular disease. The therapeutic focus is on its role in modifying vascular and cardiac parameters associated with impaired pulmonary blood flow.
- Riociguat
- Pulmonary arterial hypertension treatment
- Chronic thromboembolic pulmonary hypertension treatment
These research interests highlight a concentration on therapies targeting the pulmonary vasculature and their effects on cardiopulmonary structure and resistance.
